Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Kai Michael Beeh1 Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany, [email protected]Correspondence[email protected]

Anne-Marie Kirsten2 Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

Ana-Maria Tanase3 Novartis Pharma AG, Basel, Switzerland

Alexia Richard3 Novartis Pharma AG, Basel, Switzerland

Weihua Cao4 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Bettina Hederer3 Novartis Pharma AG, Basel, Switzerland

Jutta Beier1 Insaf Respiratory Research Institute Wiesbaden, Wiesbaden, Germany, [email protected]

Oliver Kornmann5 IKF Pneumologie, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany

Richard N van Zyl-Smit6 Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa

show all

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date